Anna Vilborg Hartwig

VP of Product Technology Development at Exai Bio
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
San Francisco Bay Area

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • VP of Product Technology Development
      • Mar 2022 - Present

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • Associate Director
      • Apr 2021 - Mar 2022

      Growing high performing teams, building innovative assays

    • Sr. Manager
      • Jan 2020 - Apr 2021

      Grown the team to a 10+ reports in a multilayered organization focused on R&D of liquid biopsy NGS assays in the CLIA and IVD space. Successfully lead assay development and validation to meet milestones including phase gate exits, regulatory approval and launch in the clinical lab.

    • Manager
      • Jun 2018 - Jan 2020

      Leading assay team through development, validation, and clinical lab transfer of NGS liquid biopsy assays, resulting in successful assay launch in CLIA lab. Assisting Regulatory department in successful communication with the FDA. Responsible for project coordination with other departments including Process Engineering, Bioinformatics, Regulatory, Quality, Lab Directors, Clinical Operations, and Supply Chain to enable new assay development with maintained support of existing CLIA assay… Show more Leading assay team through development, validation, and clinical lab transfer of NGS liquid biopsy assays, resulting in successful assay launch in CLIA lab. Assisting Regulatory department in successful communication with the FDA. Responsible for project coordination with other departments including Process Engineering, Bioinformatics, Regulatory, Quality, Lab Directors, Clinical Operations, and Supply Chain to enable new assay development with maintained support of existing CLIA assay

    • United States
    • Biotechnology
    • 1 - 100 Employee
    • Vice President R&D
      • Jan 2018 - Jun 2018

      TOMA Biosciences is a biotechnology startup company based out of Stanford University, focusing on personalized medicine diagnostics in cancer. Planning the future directions of TOMA’s R&D efforts, leading the R&D team in developing products for NGS library preparation focusing on low-quality FFPE samples, and overseeing the implementation of these products in customer laboratories

    • Director Of R&D
      • Jan 2017 - Dec 2017

      • Led the R&D team through the development and improvement of library preparation methods for targeted panels as well as whole genome sequencing adapted for low-quality FFPE samples, resulting in new products implemented by customers • Co-led strategic planning for TOMA’s R&D work 2017-2018 • Developed structures for enhanced communication, collaboration, and productivity of the R&D team

    • Senior Scientist
      • Apr 2016 - Jan 2017

      • Worked as part of an interdisciplinary R&D team to design, test, and implement improvements to the TOMA OS-Seq protocol, resulting in significantly enhanced performance of the TOMA library preparation • Presented and explained TOMA technology at conferences and to customers, contributing to the implementation of the TOMA OS-Seq technology with a number of new customers • Participated as technical expert on TOMA’s patent advisory committee.

    • United States
    • Higher Education
    • 700 & Above Employee
    • Post doc
      • 2011 - Apr 2016

      Plan and conduct research on non-coding RNAs in stress responses and cancer using innovative sequencing and genome-editing tools • Designed and performed RNA-Seq experiments, leading to the discovery of a large class of stress-inducible readthrough transcripts with potential roles in cellular stress, cancer, and viral infections. • Purposed a new method for genome-wide detection of transcriptional start sites through purification and detection of capped RNA fragments, providing the… Show more Plan and conduct research on non-coding RNAs in stress responses and cancer using innovative sequencing and genome-editing tools • Designed and performed RNA-Seq experiments, leading to the discovery of a large class of stress-inducible readthrough transcripts with potential roles in cellular stress, cancer, and viral infections. • Purposed a new method for genome-wide detection of transcriptional start sites through purification and detection of capped RNA fragments, providing the crucial mechanistic insight that this large class of non-coding RNAs that I had discovered was indeed generated by readthroguh transcription • Purposed a variety of nucleic acid technology, including CRISPR, RNA FISH, and RNA interference technologies to characterize non-coding RNA and read-through transcription • Initiated and managed local and international collaborations Show less Plan and conduct research on non-coding RNAs in stress responses and cancer using innovative sequencing and genome-editing tools • Designed and performed RNA-Seq experiments, leading to the discovery of a large class of stress-inducible readthrough transcripts with potential roles in cellular stress, cancer, and viral infections. • Purposed a new method for genome-wide detection of transcriptional start sites through purification and detection of capped RNA fragments, providing the… Show more Plan and conduct research on non-coding RNAs in stress responses and cancer using innovative sequencing and genome-editing tools • Designed and performed RNA-Seq experiments, leading to the discovery of a large class of stress-inducible readthrough transcripts with potential roles in cellular stress, cancer, and viral infections. • Purposed a new method for genome-wide detection of transcriptional start sites through purification and detection of capped RNA fragments, providing the crucial mechanistic insight that this large class of non-coding RNAs that I had discovered was indeed generated by readthroguh transcription • Purposed a variety of nucleic acid technology, including CRISPR, RNA FISH, and RNA interference technologies to characterize non-coding RNA and read-through transcription • Initiated and managed local and international collaborations Show less

    • Sweden
    • Higher Education
    • 700 & Above Employee
    • Post doc
      • 2010 - Jan 2011

      Plan and conduct research related to the tumor supressor p53

    • Graduate Student
      • Jun 2005 - Oct 2010

      Graduate student in cancer biology/RNA biology; applying numerous in vitro and in vivo cancer biology methods to the study of the p53 tumor suppressor pathway • Discovered that the Wig-1 protein, of previously unknown function and a transcriptional target of p53, is involved in regulation of mRNA stability, opening up a new avenue of Wig-1 research • Mentored junior students in the Wig-1 research team, maintained local and international collaborations • Served as a Student… Show more Graduate student in cancer biology/RNA biology; applying numerous in vitro and in vivo cancer biology methods to the study of the p53 tumor suppressor pathway • Discovered that the Wig-1 protein, of previously unknown function and a transcriptional target of p53, is involved in regulation of mRNA stability, opening up a new avenue of Wig-1 research • Mentored junior students in the Wig-1 research team, maintained local and international collaborations • Served as a Student Representative of the board for Postgraduate Research in Oncology and was involved in developing a new postgraduate course for clinicians that won a major Swedish teaching grant.

Education

  • Karolinska Institutet
    Doctor of Philosophy (Ph.D.), Biomedicine
    2006 - 2010
  • Karolinska Institutet
    M. Sc, Biomedicine
    2000 - 2005

Community

You need to have a working account to view this content. Click here to join now